The role of Granulocyte Colony-Stimulating Factor and carbapenem therapy in severe melioidosis: A case report from Malaysia

Abstract

Melioidosis is a fatal disease endemic in Southeast Asia and Australia. Type 2 diabetes mellitus is one of the main risk factors for acquiring this infectious disease. We described a case of severe melioidosis in a 31-yearold female patient with multiple hepatosplenic abscesses and underlying type 2 diabetes mellitus. The blood culture showed positive results to Burkholderia pseudomallei only after one month of on and off fever experienced by the patient. A splenectomy was done to prevent the development of peritonitis. The use of granulocyte colonystimulating Factor (G-CSF) in addition to shifting from ceftazidime to meropenem therapy played an effective role in the recovery of the patient. In this case report we reviewed the literature on the impaired immunity in type 2 diabetic patient that put the patient on risk of acquiring melioidosis and the suggested role of G-CSF and carbapenem therapy. 

Keywords

• Melioidosis
• granulocyte colony-stimulating factor
• carbapenem
• hepatosplenic abscess

References

1. Chanchamroen S, Kewcharoenwong C, Susaengrat W, Ato M, Lertmemongkolchai G. Human polymorphonuclear neutrophil responses to Burkholderia pseudomallei in healthy and diabetic subjects. Infect Immun 2009; 77:456-463.
2. Meumann EM, Cheng AC, Ward L, Currie BJ. Clinical features and epidemiology of melioidosis pneumonia: results from a 21-year study and review of the literature. Clin Infect Dis 2012; 54:362-369.
3. Inglis TJJ. The treatment of melioidosis. Pharmaceuticals 2010; 3:1296-1303.
4. Estes DM, Dow SW, Schweizer HP, Torres AG. Present and future therapeutic strategies for melioidosis and glanders. Expert Rev Anti Infect Ther 2010; 8:325-338.
5. White NJ, Dance DA, Chaowagul W, et al. Halving of mortality of severe melioidosis by ceftazidime. Lancet 1989; 2:697-701.
6. Cheng AC, Fisher DA, Anstey NM, et al. Outcomes of patients with melioidosis treated with meropenem. Antimicrob Agents Chemother 2004; 48:1763-1765.
7. Delano MJ, Thayer T, Gabrilovich S, et al. Sepsis induces early alterations in innate immunity that impact mortality to secondary infection. J Immunol 2011; 186:195-202.
8. Faivre V, Lukaszewicz AC, Alves A, et al. Human monocytes differentiate into dendritic cells subsets that induce anergic and regulatory T cells in sepsis. PLoS One 2012; 7:47209.

9. Morris J, Williams N, Rush C, et al. Burkholderia pseudomallei triggers altered inflammatory profiles in a whole-blood model of type 2 diabetes-melioidosis comorbidity. Infect Immun 2012; 80:2089-2099.
10. Cheng AC, Stephens DP, Anstey NM, Currie BJ. Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin Infect Dis 2004; 38:32-37.
11. Stephens DP, Fisher DA, Currie BJ. An audit of the use of granulocyte colony-stimulating factor in septic shock. Intern Med J 2002; 32:143-148.
12. Cheng AC, Limmathurotsakul D, Chierakul W, et al. A randomized controlled trial of granulocyte colony- stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. Clin Infect Dis 2007; 45:308-314.
13. Puthucheary SD. Melioidosis in Malaysia. Med J Malaysia 2009; 64:266-274.
14. Ben RJ, Tsai YY, Chen JC, Feng NH. Non-septicemic Burkholderia pseudomallei liver abscess in a young man. J Microbiol Immunol Infect 2004; 37:254-257.
15. Apisarnthanarak A, Apisarnthanarak P, Mundy LM. Computed tomography characteristics of Burkholderia pseudomallei liver abscess. Clin Infect Dis 2006; 42:989-993.
16. Riengchan P, Meprom N. Septicemic melioidosis and multiple splenic abscesses in a patient who lives in Bangkok. J Infect Dis Antimicrob Agents 2011; 28: 125-128.
17. Mukhopadhya A, Balaji V, Jesudason MV, et al. Isolated liver abscesses in melioidosis. Indian J Med Microbiol 2007; 25:150-151.
18. Lin CY, Chen TC, Lu PL, Lin WR, Chen YH. Melioidosis presenting with isolated splenic abscesses: a case report. Kaohsiung J Med Sci 2007; 23:417-421.
19. Ng CY, Leong EC, Chng HC. Ten-year series of splenic abscesses in a general hospital in Singapore. Ann Acad Med Singapore 2008; 37:749-752.
20. Ceriello A, Testa R. Antioxidant anti-inflammatory treatment in type 2 diabetes. Diabetes Care 2009; 32: 232-236.
21. Riyapa D, Buddhisa S, Korbsrisate S, et al. Neutrophil extracellular traps exhibit antibacterial activity against Burkholderia pseudomallei and are influenced by bacterial and host factors. Infect Immun 2012; 80: 3921-3929.
22. Koh GC, Maude RR, Schreiber MF, et al. Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis. Clin Infect Dis 2011; 52: 717-725.
23. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996; 88:1907-1929.
24. Laowansiri P, Shah S, Kiratisin P, et al. A role for carbapenem in the treatment of melioidosis in developing countries? Int J Infect Dis 2009; 13:331- 332.
25. Simpson AJ, Opal SM, Angus BJ, et al. Differential antibiotic-induced endotoxin release in severe melioidosis. J Infect Dis 2000; 181:1014-1019.
26. Walsh AL, Smith MD, Wuthiekanun V, White NJ. Postantibiotic effects and Burkholderia (Pseudomonas) pseudomallei: evaluation of current treatment. Antimicrob Agents Chemother 1995; 39:2356-2358.
27. Smith MD, Wuthiekanun V, Walsh AL, White NJ. Susceptibility of Pseudomonas pseudomallei to some newer beta-lactam antibiotics and antibiotic combinations using time-kill studies. J Antimicrob Chemother 1994; 33:145-149.
28. Basil JH, Chong CP. Carbapenem associated seizure in a severe melioidosis patient: a case report. East J Med 2013; 18:92-96.
29. Wu YC, Hsu JW, Chang TH, Kung WC. Melioidosis in an urban-dwelling Taiwanese man with splenic abscesses. Trop Doct 2010; 40:240-241.